Cargando…

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin

Breast cancers can be divided into several types. Because triple-negative breast cancer (TNBC) is the most refractory to current anti-cancer therapies, efficient treatment has been urgently required. Members of the Bcl-2 family play pro- and anti-apoptotic roles in mitochondria-mediated apoptosis. S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inao, Touko, Iida, Yuichi, Moritani, Tamami, Okimoto, Tamio, Tanino, Ryosuke, Kotani, Hitoshi, Harada, Mamoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986635/ https://www.ncbi.nlm.nih.gov/pubmed/29876007 http://dx.doi.org/10.18632/oncotarget.25370

Ejemplares similares

Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
por: Inao, Touko, et al.
Publicado: (2019)

Chloroquine augments TRAIL-induced apoptosis and induces G2/M phase arrest in human pancreatic cancer cells
por: Monma, Hiroyuki, et al.
Publicado: (2018)

Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
por: Okimoto, Tamio, et al.
Publicado: (2020)

Protective role of cytoplasmic p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor‐induced senescence in breast cancer cells
por: Kartika, Irna D., et al.
Publicado: (2021)

Protective roles of cytoplasmic p21(Cip1) (/Waf1) in senolysis and ferroptosis of lung cancer cells
por: Koyanagi, Akira, et al.
Publicado: (2022)

Immunogenic chemotherapy in two mouse colon cancer models
por: Taniura, Takahito, et al.
Publicado: (2020)

Supplementation of l‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
por: Satoh, Yusuke, et al.
Publicado: (2020)

The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer Cells
por: Zhang, Min, et al.
Publicado: (2015)

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
por: Tong, Xuexia, et al.
Publicado: (2019)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
por: Iida, Yuichi, et al.
Publicado: (2020)

Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL
por: Hari, Yoko, et al.
Publicado: (2015)

Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer
por: Tanino, Ryosuke, et al.
Publicado: (2018)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer
por: Bawaneh, Alaa, et al.
Publicado: (2022)

Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis
por: Kawabata, Yasunari, et al.
Publicado: (2010)

Characterization of a spontaneous mouse model of mild, accelerated aging via ECM degradation in emphysematous lungs
por: Tanino, Ryosuke, et al.
Publicado: (2023)

Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
por: Chen, Dar-Ren, et al.
Publicado: (2014)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition
por: Tamaki, Hiroki, et al.
Publicado: (2014)

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Kanakaveti, Vishnupriya, et al.
Publicado: (2022)

The Association Between Cyclooxygenase-2 –1195G/A (rs689466) Gene Polymorphism and the Clinicopathology of Lung Cancer in the Japanese Population: A Case-Controlled Study
por: Sun , Rong, et al.
Publicado: (2022)

Metachronous bilateral triple-negative breast cancer associated with neurofibromatosis type 1: A case report
por: Yamagishi, Yoji, et al.
Publicado: (2019)

Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer
por: Skov, Natascha, et al.
Publicado: (2022)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
por: Krausz, Aimee E., et al.
Publicado: (2018)

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo
por: Lothstein, Leonard, et al.
Publicado: (2020)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy
por: Zhou, Jingyi, et al.
Publicado: (2023)

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
por: Zeng, Weiwei, et al.
Publicado: (2023)

Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2015)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer
por: McKenna, Matthew T., et al.
Publicado: (2017)

The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells
por: Mentoor, Ilze, et al.
Publicado: (2021)

Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer
por: Lee, Kevin J, et al.
Publicado: (2021)

Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer
por: Velenosi, Thomas J., et al.
Publicado: (2022)

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer
por: Tomiguchi, Mai, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ceqgl2eqhn6p90a2cng9ohub04